Table of Contents
Pravastatin-Aspirin Combination The Medical Need
Consistency of the Efficacy Findings
Pravastatin-Aspirin Patient Population
U.S. Heart Disease Prevalence Is Projected to Double in the Next Half Century
AHA/ACC Guidelines Update in Patients with Atherosclerotic CV Disease
Components of the Treatment Gap in the Secondary Prevention of Coronary Disease
Following New AHA/ACC Guidelines Necessitates High Pill Burden
Improved Compliance with Combination Tablet vs. Dual Therapy
Components of the Treatment Gap in the Secondary Prevention of Coronary Disease
Sub-Optimal Usage at Discharge of CV Therapies with Proven Value
Components of the Treatment Gap in the Secondary Prevention of Coronary Disease
Sub-Optimal Use of Efficacious Statin Doses: The LTAP Study
Sub-Optimal Use of Aspirin in Secondary Prevention
Conclusions
PPT Slide
|